HRP20230985T1 - Farmaceutske formulacije pegiliranih liposoma i faktora koagulacije krvi - Google Patents
Farmaceutske formulacije pegiliranih liposoma i faktora koagulacije krvi Download PDFInfo
- Publication number
- HRP20230985T1 HRP20230985T1 HRP20230985TT HRP20230985T HRP20230985T1 HR P20230985 T1 HRP20230985 T1 HR P20230985T1 HR P20230985T T HRP20230985T T HR P20230985TT HR P20230985 T HRP20230985 T HR P20230985T HR P20230985 T1 HRP20230985 T1 HR P20230985T1
- Authority
- HR
- Croatia
- Prior art keywords
- use according
- pharmaceutical preparation
- optionally
- amphipathic lipid
- colloidal particle
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 5
- 102000015081 Blood Coagulation Factors Human genes 0.000 title 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 title 1
- 239000003114 blood coagulation factor Substances 0.000 title 1
- 229940019700 blood coagulation factors Drugs 0.000 title 1
- 239000002502 liposome Substances 0.000 title 1
- 239000002245 particle Substances 0.000 claims 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims 10
- 150000002632 lipids Chemical class 0.000 claims 9
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 6
- 229920001223 polyethylene glycol Polymers 0.000 claims 6
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 claims 5
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- 229960000182 blood factors Drugs 0.000 claims 3
- 229920001477 hydrophilic polymer Polymers 0.000 claims 3
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 2
- ZGCHLAJIRWDGFE-UHFFFAOYSA-N 1-aminopropane-1,1-diol Chemical compound CCC(N)(O)O ZGCHLAJIRWDGFE-UHFFFAOYSA-N 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 1
- 108010054218 Factor VIII Proteins 0.000 claims 1
- 102000001690 Factor VIII Human genes 0.000 claims 1
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 1
- 229920000954 Polyglycolide Polymers 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4866—Protein C (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
- A61K9/1278—Post-loading, e.g. by ion or pH gradient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1417589.7A GB201417589D0 (en) | 2014-10-06 | 2014-10-06 | Pharmaceutical Formulations |
| EP15775444.1A EP3204034B9 (en) | 2014-10-06 | 2015-10-06 | Pharmaceutical formulations of pegylated liposomes and blood coagulation factors |
| PCT/EP2015/073003 WO2016055447A1 (en) | 2014-10-06 | 2015-10-06 | Pharmaceutical formulations of pegylated liposomes and blood coagulation factors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230985T1 true HRP20230985T1 (hr) | 2023-12-08 |
Family
ID=51946871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230985TT HRP20230985T1 (hr) | 2014-10-06 | 2015-10-06 | Farmaceutske formulacije pegiliranih liposoma i faktora koagulacije krvi |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20170304203A1 (enExample) |
| EP (1) | EP3204034B9 (enExample) |
| JP (3) | JP2017531659A (enExample) |
| AU (1) | AU2015330102B2 (enExample) |
| BR (1) | BR112017007031A2 (enExample) |
| CA (1) | CA2994891C (enExample) |
| ES (1) | ES2954134T3 (enExample) |
| GB (1) | GB201417589D0 (enExample) |
| HR (1) | HRP20230985T1 (enExample) |
| HU (1) | HUE063656T2 (enExample) |
| MX (1) | MX384517B (enExample) |
| PL (1) | PL3204034T3 (enExample) |
| RS (1) | RS64461B1 (enExample) |
| RU (1) | RU2737291C2 (enExample) |
| SM (1) | SMT202300271T1 (enExample) |
| WO (1) | WO2016055447A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201417589D0 (en) * | 2014-10-06 | 2014-11-19 | Cantab Biopharmaceuticals Patents Ltd | Pharmaceutical Formulations |
| JP6825010B2 (ja) * | 2016-05-26 | 2021-02-03 | ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ | 遠心法によるリポソーム調製のための方法及び装置 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US6326353B1 (en) | 1993-03-23 | 2001-12-04 | Sequus Pharmaceuticals, Inc. | Enhanced circulation effector composition and method |
| DE69418334T2 (de) | 1993-08-06 | 2000-01-27 | Opperbas Holding B.V., Amsterdam | Verfahren zur hohen beladung von vesikeln mit biopolymeren substanzen |
| IL113010A (en) * | 1994-03-31 | 1999-10-28 | Pharmacia & Upjohn Ab | Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
| US6156337A (en) * | 1994-07-08 | 2000-12-05 | Opperbas Holding B.V. | Method for high loading of vesicles with biopolymeric substances |
| US6310183B1 (en) * | 1997-09-10 | 2001-10-30 | Novo Nordisk A/S | Coagulation factor VIIa composition |
| MXPA00010241A (es) * | 1998-04-27 | 2004-09-06 | Opperbas Holding Bv | Composicion farmaceutica que comprende el factor viii y liposomas neutrales.. |
| RU2250911C2 (ru) * | 1999-07-14 | 2005-04-27 | Элзэ Копэрейшн | Липосомальная композиция, нейтральный липополимер и способ увеличения времени циркуляции липосомы |
| AU2001256148A1 (en) * | 2000-05-03 | 2001-11-12 | Novo-Nordisk A/S | Subcutaneous administration of coagulation factor vii |
| US20030232075A1 (en) | 2002-05-06 | 2003-12-18 | University Of Minnesota, A Minnesota Corporation | Compositions for producing factor Xa |
| DE602004013769D1 (de) | 2003-04-15 | 2008-06-26 | Opperbas Holding Bv | Pharmazeutische zusammensetzung, enthaltend proteine und/oder polypeptide sowie kolloidpartikel |
| JP2008544990A (ja) * | 2005-06-29 | 2008-12-11 | ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク | 低免疫原性蛋白質−脂質複合体に関する組成物および方法 |
| EP2099475B1 (en) * | 2007-01-03 | 2016-08-24 | Novo Nordisk Health Care AG | Subcutaneous administration of coagulation factor viia-related polypeptides |
| CA2701884A1 (en) | 2007-10-15 | 2009-04-23 | Wake Forest University Health Sciences | Methods and compositions for printing biologically compatible nanotube composites of autologous tissue |
| AU2010255391C1 (en) | 2009-06-03 | 2016-10-27 | Sequessome Technology Holdings Limited | Formulations for the treatment of deep tissue pain |
| MX336482B (es) | 2009-08-21 | 2016-01-21 | Henk-Andre Kroon | Formulaciones vesiculares. |
| GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
| GB201007357D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIII |
| TW201240664A (en) * | 2010-09-01 | 2012-10-16 | Portola Pharm Inc | Methods and formulations of treating thrombosis with betrixaban and a P-glycoprotein inhibitor |
| EP2838566A2 (en) * | 2012-04-16 | 2015-02-25 | Cantab Biopharmaceuticals Patents Limited | Optimised subcutaneous therapeutic agents |
| GB201417589D0 (en) * | 2014-10-06 | 2014-11-19 | Cantab Biopharmaceuticals Patents Ltd | Pharmaceutical Formulations |
-
2014
- 2014-10-06 GB GBGB1417589.7A patent/GB201417589D0/en not_active Ceased
-
2015
- 2015-10-06 ES ES15775444T patent/ES2954134T3/es active Active
- 2015-10-06 CA CA2994891A patent/CA2994891C/en active Active
- 2015-10-06 WO PCT/EP2015/073003 patent/WO2016055447A1/en not_active Ceased
- 2015-10-06 EP EP15775444.1A patent/EP3204034B9/en active Active
- 2015-10-06 JP JP2017518466A patent/JP2017531659A/ja active Pending
- 2015-10-06 HU HUE15775444A patent/HUE063656T2/hu unknown
- 2015-10-06 HR HRP20230985TT patent/HRP20230985T1/hr unknown
- 2015-10-06 RS RS20230695A patent/RS64461B1/sr unknown
- 2015-10-06 SM SM20230271T patent/SMT202300271T1/it unknown
- 2015-10-06 MX MX2017004378A patent/MX384517B/es unknown
- 2015-10-06 RU RU2017115831A patent/RU2737291C2/ru active
- 2015-10-06 AU AU2015330102A patent/AU2015330102B2/en not_active Ceased
- 2015-10-06 PL PL15775444.1T patent/PL3204034T3/pl unknown
- 2015-10-06 BR BR112017007031A patent/BR112017007031A2/pt active Search and Examination
- 2015-10-06 US US15/517,148 patent/US20170304203A1/en not_active Abandoned
-
2018
- 2018-08-01 US US16/052,300 patent/US11484499B2/en active Active
-
2020
- 2020-07-30 JP JP2020129101A patent/JP2020183446A/ja active Pending
-
2022
- 2022-10-20 JP JP2022168146A patent/JP7573582B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HUE063656T2 (hu) | 2024-01-28 |
| JP7573582B2 (ja) | 2024-10-25 |
| JP2023002687A (ja) | 2023-01-10 |
| AU2015330102A1 (en) | 2017-05-25 |
| RS64461B1 (sr) | 2023-09-29 |
| EP3204034A1 (en) | 2017-08-16 |
| CA2994891A1 (en) | 2016-04-14 |
| CA2994891C (en) | 2023-04-04 |
| US20170304203A1 (en) | 2017-10-26 |
| JP2017531659A (ja) | 2017-10-26 |
| WO2016055447A1 (en) | 2016-04-14 |
| EP3204034B9 (en) | 2023-10-04 |
| EP3204034C0 (en) | 2023-06-07 |
| US11484499B2 (en) | 2022-11-01 |
| RU2017115831A3 (enExample) | 2019-05-06 |
| RU2017115831A (ru) | 2018-11-14 |
| US20190060235A1 (en) | 2019-02-28 |
| MX384517B (es) | 2025-03-14 |
| EP3204034B1 (en) | 2023-06-07 |
| SMT202300271T1 (it) | 2023-09-06 |
| ES2954134T3 (es) | 2023-11-20 |
| GB201417589D0 (en) | 2014-11-19 |
| MX2017004378A (es) | 2018-02-09 |
| JP2020183446A (ja) | 2020-11-12 |
| PL3204034T3 (pl) | 2023-11-06 |
| BR112017007031A2 (pt) | 2018-01-30 |
| AU2015330102B2 (en) | 2021-01-28 |
| RU2737291C2 (ru) | 2020-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Molinaro et al. | Leukocyte-mimicking nanovesicles for effective doxorubicin delivery to treat breast cancer and melanoma | |
| Ferreira et al. | pH-sensitive liposomes for drug delivery in cancer treatment | |
| Rajera et al. | Niosomes: a controlled and novel drug delivery system | |
| JP6751424B2 (ja) | ダイズホスファチジルセリンで作られたコクリエート | |
| Wauthoz et al. | Phospholipids in pulmonary drug delivery | |
| JP6535281B2 (ja) | 関節炎の処置方法 | |
| CN102630175B (zh) | Spla2可水解脂质体的医药用途 | |
| US20170281541A1 (en) | Liposome-based mucus-penetrating particles for mucosal delivery | |
| CN108024960A (zh) | 含有阴离子药物的药物组合物及其制备方法 | |
| Griffin et al. | Revealing dynamics of accumulation of systemically injected liposomes in the skin by intravital microscopy | |
| US20170072033A1 (en) | Liposomal compositions for mucosal delivery | |
| Mozafari et al. | An overview of liposome-derived nanocarrier technologies | |
| AU2015352688A1 (en) | Pharmaceutical composition, preparation and uses thereof | |
| Li et al. | Colistin-entrapped liposomes driven by the electrostatic interaction: mechanism of drug loading and in vivo characterization | |
| JP2010518012A (ja) | カンプトテシン誘導体を含む医薬組成物 | |
| HRP20230985T1 (hr) | Farmaceutske formulacije pegiliranih liposoma i faktora koagulacije krvi | |
| JP2018535952A5 (enExample) | ||
| CA2595485A1 (en) | Liposomal compositions for parenteral delivery of statins | |
| KR20220149400A (ko) | 이황화 결합을 갖는 양이온성 지질을 사용하여 약물을 전달하기 위한 나노입자 조성물 및 그 제조방법 | |
| CN103800911B (zh) | 可消除peg化纳米载体abc现象的方法 | |
| JP2017531659A5 (enExample) | ||
| TWI857961B (zh) | 減少關節內類固醇的併發症之方法 | |
| Bakardzhiev et al. | Novel polyglycidol-lipid conjugates create a stabilizing hydrogen-bonded layer around cholesterol-containing dipalmitoyl phosphatidylcholine liposomes | |
| WO2003022250A2 (en) | Unilamellar vesicles stabilized with short chain hydrophilic polymers | |
| TW202220668A (zh) | 用於疼痛控制之關節內皮質類固醇的藥學組成物 |